^
    Back
    Association details:
    Biomarker:TNFRSF8 negative
    Cancer:Peripheral T-cell Lymphoma
    Drug:Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2021
    Title:

    COMPARISON OF CHIDAMIDE-CONTAINED TREATMENT MODALITIES VERSUS CHEMOTHERAPY IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

    Published date:
    05/12/2021
    Excerpt:
    In the subgroup of CD30(-) patients, PFS was superior in the Chidamide+ChT group as compared with other groups (p =0.002, Figure 5)….first retreatment with chidamide+ChT regimen showed more PFS benefit than ChT and targeted therapy for RR PTCL patients, especially those with high second-line IPI, younger than 60 years and CD30(-).
    Secondary therapy:
    Chemotherapy